Cargando…

Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways

Despite significant progress, advanced hepatocellular carcinoma (HCC) remains an incurable disease, and the overall efficacy of targeted therapy by Sorafenib remains moderate. We hypothesized that DCP (des-gamma-carboxy prothrombin), a prothrombin precursor produced in HCC, might be one of the reaso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Shu-Xiang, Shi, Wen-Na, Song, Zhi-Yu, Wang, Shu-Qing, Yu, Xin-Feng, Gao, Zu-Hua, Qu, Xian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095038/ https://www.ncbi.nlm.nih.gov/pubmed/27167344 http://dx.doi.org/10.18632/oncotarget.9168

Ejemplares similares

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases
por: Nakazawa, Takahide, et al.
Publicado: (2010)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways
por: Wang, Ligang, et al.
Publicado: (2023)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis
por: Chen, Jiu, et al.
Publicado: (2018)

The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages
por: Nagahara, Takakazu, et al.
Publicado: (2023)

Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis
por: Zhu, Rong, et al.
Publicado: (2014)

Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin
por: Kurokawa, Tomoharu, et al.
Publicado: (2016)

A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma
por: De, Ji, et al.
Publicado: (2016)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway
por: Qian, Jun, et al.
Publicado: (2020)

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram
por: Sun, Ting, et al.
Publicado: (2021)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas—New Potential Therapeutic Approach—A Systematic Review
por: Derwich, Aleksandra, et al.
Publicado: (2023)

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway
por: Du, Wei, et al.
Publicado: (2012)

Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma
por: Yamazaki, Shintaro, et al.
Publicado: (2020)

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
por: Wang, Xiaojuan, et al.
Publicado: (2020)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

Global view of the RAF-MEK-ERK module and its immediate downstream effectors
por: Santini, Cristina C., et al.
Publicado: (2019)

Porcine deltacoronavirus activates the Raf/MEK/ERK pathway to promote its replication
por: Jeon, Ji Hyun, et al.
Publicado: (2020)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma
por: Núñez, Kelley G., et al.
Publicado: (2021)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
por: McArthur, Grant A.
Publicado: (2015)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

A Novel LC‐MS/MS Assay for Quantification of Des‐carboxy Prothrombin and Characterization of Warfarin‐Induced Changes
por: Basit, Abdul, et al.
Publicado: (2020)

Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway
por: Zheng, Jie, et al.
Publicado: (2014)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study
por: Ji, Jun, et al.
Publicado: (2016)

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
por: Lee, Yong Kang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q548m38a7mt2kiu01lsnn9m2p4